

(Translation)

January 17, 2025

Company name: Riken Vitamin Co., Ltd.
Name of representative: Kazuhiko Yamaki
President and Representative Director
(Securities code: 4526; Tokyo Stock
Exchange Prime Market)
Inquiries: Yuichi Nakagawa
General Manager of Corporate Planning
Department, Chief Manager of Corporate
Planning Division
(Tel: 03-5362-1315)

Notice Regarding Recording of Extraordinary Income (Gain on Sale of Investment Securities)

Riken Vitamin Co., Ltd. (the "Company") hereby announces that it has recorded extraordinary income (gain on sale of investment securities) due to the sale of some investment securities, as follows.

1. Reason for the sale of investment securities

To reduce cross-shareholdings.

2. Details of the gain on sale of investment securities

- | | |
|--|--|
| (1) Shares sold: | Securities of one listed company held by the Company |
| (2) Date of sale: | January 17, 2025 |
| (3) Gain on sale of investment securities: | ¥1,613 million |

3. Outlook

The gain on sale of investment securities will be recorded as extraordinary income in the fourth quarter ending March 31, 2025. The impact of this gain has already been incorporated into the full-year earnings forecast for the fiscal year ending March 31, 2025, which was announced on May 10, 2024. If it becomes necessary to revise the earnings forecast for any reason, we will announce it promptly.